Dexpanthenol
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
- Dexpanthenol
- Pharmacist Assessment Report
- Dexpanthenol: Provitamin of pantothenic acid (coenzyme A precursor) → anorectal stricture
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Dexpanthenol: Provitamin of pantothenic acid (coenzyme A precursor) → anorectal stricture
One-Sentence Summary
Dexpanthenol is a provitamin of pantothenic acid, used to support skin and mucosal repair. The TxGNN model predicts it may be relevant to anorectal stricture, with a score of 0.9972. There are currently no clinical trials and no publications that directly study this condition, so the support is model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | anorectal stricture |
| TxGNN Prediction Score | 0.9972 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Dexpanthenol is a provitamin of pantothenic acid, a precursor of coenzyme A, and is thought to support epithelial repair and wound healing.
A plausible but unproven link exists between this repair role and mucosal healing in anorectal tissue. However, anorectal stricture is a fibrotic, narrowing condition, whereas dexpanthenol’s gastrointestinal uses concern motility rather than scarring. The mechanistic link is therefore speculative, and no clinical or published evidence was available to test it.
Clinical Trial Evidence
Currently no related clinical trials registered for anorectal stricture.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02100606 | MULTI 12 | Not recorded | Not recorded |
| 02242529 | MULTI-12/K1 PEDIATRIC | Not recorded | Not recorded |
Both licences are currently valid.
Safety Considerations
- Drug Interactions: No interaction records were found.
Please refer to the package insert for further safety information, such as warnings and contraindications, which were not available in the compiled data.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but no clinical trials or publications address anorectal stricture, and the proposed mechanism is unproven. The evidence level is therefore L5.
To proceed, the following is needed:
- Mechanism-of-action data for dexpanthenol
- Preclinical or clinical studies of dexpanthenol in anorectal stricture or related mucosal fibrosis
- Health Canada package insert warnings and contraindications
- Assessment of route and formulation compatibility for anorectal use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.